Kornimate/medical-research-clean huggingface dataset:
the purpose of the study is to investigate if a smartphone app combined with internet based cognitive behavioural therapy (icbt) leads to improved symtoms in depressive adults on antidepressive medicine, compared to a wait-list control condition

Conditions: Depressive Symptoms

Summary: the purpose of the study is to investigate if a smartphone app combined with internet delivered cognitive behavioural therapy (icbt) leads to improved symptoms in depressive adults on antidepressive mediation. the participants in the treatment group will get access to a smartphone app based on cbt-principles for 9 weeks. they will also get access to an internet platform with extra treatment material based on cbt and receive therapist support on demand. participants will be recruited in sweden with nationwide recruitment.

this study is a randomized controlled trial with the aim to investigate if an smartphone app in combination with icbt can help adults (+18) on antidepressant medication who still suffers from depressive symptoms. participants will either be randomized to a treatment phase for 9 weeks or to a wait-list control. the treatment primarily contains the installation and usage of a smartphone app where the participants can engage in a serious mobile game based on cbt-principles. they will receive access to a secure internet platform where they can find general guidelines about the app, and extra treatment modules (to use if needed). they will receive support on demand from a therapist during the whole treatment period. primary outcome measure is depressive symptoms (measured on the madras scale). secondary outcome measures will include measures of anxiety and quality of life. pre-treatment measurement, post-treatment measurement, weekly measure, and 24 \& 36 months follow up is planned to be collected through an online survey.

Eligibility criteria:
inclusion criteria: * ongoing drug treatment with an antidepressant mediated by an established care contact in (primary) care. * 18 years or older. * be able to speak, read and write swedish. * have access to a computer, tablet or other device with internet connection and smartphone to download the app. exclusion criteria: * severe psychiatric or somatic problems that make participation difficult or impossible * ongoing abuse (via audit and during interview) * acute suicidality * other ongoing psychological treatment or planned investigation. * planned dose change of medicine or change of medicine during pre-measurement.

Keywords: depressive symtoms smartphone app mobile game internet-based cognitive behavioural therapy
a qualitative and quantitative analysis on the living history of survivors from charcoal-burning suicide

Conditions: Suicide

Summary: the current study aims to explore the risk factors, protective factors, resilient factors, and factors jeopardizing the recovery progress on survivors from charcoal-burning suicide. to this end, an in-depth individual interview and mini-mental state examination(mmse) will be used to acquire the first-hand information on the attempters. as well, a more comprehensive neuropsychological test, wais iii, will be administered at 3-month, 6-month, and 12-month after the index suicide attempt.


Eligibility criteria:
inclusion criteria: * above 20 years old, survivors from charcoal-burning suicide. exclusion criteria: * under 20 years old * survivors from other kind of suicide * prisoner * suffer from a serious illness * foreigner/ can't speak chinese * the people who can't express themselves * can not be interviewed in femh * people with severe physical or psychological symptoms

Keywords: in-depth individual interview charcoal-burning suicide
a preliminary clinical study to evaluate fispemifene in the treatment of hypogonadism

Conditions: Hypogonadism

Summary: the purpose of this study is to determine whether one or more fispemifene dose regimens are more effective than placebo in the treatment of hypogonadism in older men.


Eligibility criteria:
inclusion criteria: * total testosterone level \<240 ng/dl * serum lh and fsh levels within normal limits exclusion criteria: * elevated prolactin * evidence of benign prostatic hypertrophy * history of or current breast cancer, prostate cancer, abnormal dre or elevated psa or any other malignancy * clinically significant endocrine/metabolic or cardiovascular disease * significant polycythemia

Keywords: hypogonadism testosterone
comparing a direct versus an indirect approach to measuring the portalsytemic pressure gradients

Conditions: Liver Cirrhosis

Summary: the objective of this study is to evaluate the correlation of the calculated portosystemic pressure gradient (ppg) obtained by direct portal and hepatic pressure measurements with the echotip® insight™ and indirect portal vein pressure measurements using the interventional radiology based hepatic venous pressure gradient (hvpg) procedure.


Eligibility criteria:
inclusion criteria: * patients with cirrhosis who have been referred for a procedure where hvpg is obtained. exclusion criteria: * patient is pregnant, breast-feeding, or planning to become pregnant during the course of the study * patient is unwilling or unable to sign and date the informed consent * patient is unwilling to comply with the follow-up study schedule * previous total or partial splenectomy * non-cirrhotic portal hypertension * known history of spontaneous bacterial peritonitis (sbp) within the last three months irrespective of treatment for sbp * patients with known infection which is not controlled by medical intervention * portopulmonary hypertension * cardiac decompensation * pre-sinusoidal liver disease * cholestatic liver disease * patient who received endoscopic treatment for upper gastrointestinal (gi) variceal bleeding within the past 7 days * patients with current hepatocellular carcinoma (hcc)

Keywords: portal pressure measurement portal pressure gradient hepatic vein pressure gradient liver diseases portal hypertension intractable ascites end stage liver disease
endometrial changes in breast cancer women.

Conditions: Endometrial Cancer; Endometrial Hyperplasia With Atypia; Breast Cancer; TAM

Summary: this is a prospective observational multicentric study. the aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant therapies. the second aim is to identify ultrasonographic soft markers related with endometrial cancer or atipycal hyperplasia.

this is a prospective observational multicentric study. patient with a history of breast cancer treated with adjuvant hormonal therapies or with no therapies, will be enrolled and followed once a year with physical exam and endovaginal ultrasound. patients with suspected endometrial pathology will undergo hysteroscopy with endometrial biopsy or endometrial lesion resection. the aim is to evaluate the incidence of endometrial cancer and endometrial atypical hyperplasia in patients with previous breast cancer, treated with different adjuvant therapies. the second aim is to identify ultrasonographic soft markers related with endometrial cancer or atipycal hyperplasia.

Eligibility criteria:
inclusion criteria: * personal history of breast cancer exclusion criteria: * personal history of other hormonal sensitive cancers * assumption of hormones in the previous 5 years * previous medical assisted reproduction technique * lynch syndrome or brca 1/2 mutations
an observational study of pegasys (peginterferon alfa-2a) in patients with chronic hepatitis b who have failed antiviral treatment with nucleoside (nucleotide) analogues

Conditions: Hepatitis B, Chronic

Summary: this observational study will evaluate the efficacy and safety of pegasys (peginterferon alfa-2a) in patients with chronic hepatitis b who have failed antiviral treatment with nucleoside (nucleotide) analogues. data will be collected from patients treated according to the current summary of product characteristics and local standard of care and regulations during 48 weeks of treatment and 24 weeks of follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, \>/= 18 years of age * positive hbsag for more than 6 months before assignment to treatment with pegasys * detectable hbv dna (as measured by pcr) * hbeag positive and negative patients * patients previously treated with nucleoside (nucleotide) analogues who have failed antiviral treatment and have been assigned to treatment with pegasys according to the local therapeutic standard * elevated serum alanine aminotransferase (alt) * chronic hepatitis b confirmed by liver biopsy or non-invasive assessment (fibroscan), arfi, fibrotest) or by clinical evaluation exclusion criteria: * contraindications to treatment with pegasys according to the summary of product characteristics * hepatocellular carcinoma and/or severe hepatic dysfunction or decompensated cirrhosis of the liver * immunosuppression, immunomodulatory or chemotherapy within the last 6 months prior to start of pegasys treatment * planned other than pegasys antiviral treatment during pegasys therapy * chronic liver disease other than chronic hepatitis b * pregnant or breast-feeding women * inadequate hematologic function * autoimmunology disorders * co-infection with chronic hepatitis c or hiv
using virtual reality to improve job reentry in adults with tbi

Conditions: Traumatic Brain Injury

Summary: the purpose of this research is to investigate the effectiveness of virtual reality (vr) to improve job reentry skills in individuals with tbi.

the current study will examine a virtual reality (vr) intervention entitled "virtual reality job interview training (vr-jit)" which targets social competency skills needed for successful job interviewing, and its efficacy when applied to individuals with traumatic brain injury (tbi). preliminary evidence suggests that the vr-jit is successful in individuals with autism spectrum disorder and schizophrenia in improving interview abilities. however, the efficacy of vr-jit has not been evaluated in tbi populations.

Eligibility criteria:
inclusion criteria: * i am between the ages of 18 and 65. * i have a diagnosis with moderate to severe tbi. * i am at least one year post injury. * i am able to speak and read english fluently. exclusion criteria: * i have a history of multiple sclerosis, stroke, seizures or another neurological injury or disease in the past (like brain tumor or epilepsy). * i have a history of significant psychiatric illness (like bipolar disorder, schizophrenia or psychosis). * i am currently taking steroids and/or benzodiazepines as determined by study staff review of my medications.
study of innovative drug treatment therapy for pediatric mitral regurgitation

Conditions: Congenital Mitral Insufficiency

Summary: the goal of this observational study is to compare the safety and effectiveness of a modified drug therapy with traditional drug therapy in pediatric patients with mild to moderate mitral valve regurgitation. the main questions it aims to answer are: * can a modified drug therapy improve both left ventricular and mitral valve function in pediatric patients with mild to moderate mitral valve regurgitation? * can the adverse drug reactions caused by the modified drug therapy be non-inferior (clinically acceptable) to those of the traditional drug therapy? participants will be assigned to either the modified drug therapy group (comprising angiotensin-converting enzyme inhibitor (ace-i), beta-blockers, diuretics, potassium supplements, and spironolactone) or the traditional drug therapy group (diuretics and potassium supplements) based on personal preferences and clinical assessments by their attending physicians. they will undergo a one-year course of medication. additionally, echocardiography, electrocardiograms, complete blood counts, biochemical tests, and measurements of n-terminal pro-brain natriuretic peptide (nt-probnp) were conducted before the initiation of medication therapy and at 3 months, 6 months, and 12 months after treatment commencement. researchers will compare the modified drug therapy group and the traditional drug therapy group to see if the recurrence rate of moderate to severe mitral valve regurgitation, as assessed by echocardiography after 12 months of treatment, is lower in the former than in the latter.


Eligibility criteria:
inclusion criteria: * \< 14 years old * had not undertake mitral valve surgery before * moderate to severe mitral regurgitation exclusion criteria: * moderate to severe mitral regurgitation which concommitant with other cardiac malformation which can not be correct or can only perform palliative surgery * concommitant with mitral stenosis * ischemic mitral regurgitation (for example, concommitant with anomalous origin of coronary artery) * barlow syndrome * dysplasia of mitral leaflet * complete/partial endocardial cushion defect * common atrioventricular valve * atrioventricular common channel * cardiomyopathy * other mitral valve surgery contraindications * moderate to severe mitral regurgitation requires mitral valve surgery

Keywords: congenital heart disease mitral regurgitation drug therapy
early prediction of gestational diabetes in high-risk women based on breath metabolomics

Conditions: Gestational Diabetes

Summary: this study aim to develope novel breath markers of gestational diabetes through a prospective high-risk population cohort study and achieve early prediction of gestational diabetes based on an interpretable machine learning model.


Eligibility criteria:
eligibility criteria * 18-55 years old * 11-14 weeks of pregnancy * at least one risk factor for gdm * signed a written informed consent exclusion criteria: * diabetes mellitus or abnormal glucose metabolism before pregnancy * hyperemesis gravidarum (urine ketone positive)) * thyroid dysfunction * asthmatic patients * hypertensive diseases that are difficult to control * severe hepatic and renal insufficiency or severe electrolyte disturbance * malignant tumor * acute inflammation * lung disease * patients with gastritis, duodenum and other digestive system diseases * those with upper respiratory or oral problems who cannot cooperate with expiratory collection * smoker
pulmonary infection after ischemic stroke

Conditions: Had a Computed Tomography Scan of the Chest Within 24 Hours After Stroke Onset

Summary: to assess the frequency of signs of pulmonary infection on a chest ct and development of clinical diagnose of poststroke pneumonia，and its effect on functional outcome in patients with acute ischemic stroke.


Eligibility criteria:
inclusion criteria: have a computed tomography scan of the chest within 24 hours after stroke onset exclusion criteria: -
a trial of pelvic floor chemodenervation in patients undergoing physical therapy for high tone pelvic floor dysfunction

Conditions: Pelvic Pain; Dyspareunia; Pelvic Floor Dysfunction

Summary: this study assesses whether the addition of chemodenervation to an established regimen of pelvic floor physical therapy for painful high tone pelvic floor dysfunction improves patients' objective and subjective outcomes. study subjects will select one of three treatment approaches: injection of 50 units botulinum toxin a with local sedation as an office procedure, injection of 100u bonta-cosmetic in either the office or while anesthetized, or injection of 150 units botulinum toxin a while anesthetized.

high-tone pelvic floor dysfunction is often a painful condition that can be associated with a number of female pelvic syndromes including childhood elimination disorders, idiopathic urinary retention, vaginismus, dyspareunia, pelvic pain, constipation, sport injuries, postoperative and bladder pain syndrome/interstitial cystitis. following appropriate patient education about pelvic floor function, mainstays of therapy for high-tone pelvic floor dysfunction pelvic pain include pharmacotherapeutic agents and pelvic floor physical therapy. the investigators hypothesize that chemodenervation with botulinum toxin a will offer a safe, efficacious intervention for women with high tone pelvic floor dysfunction that cannot be adequately treated with pelvic floor physical therapy alone.

Eligibility criteria:
inclusion criteria: * age 18 years or older * \>6 month history of pelvic pain or dyspareunia with high tone pelvic floor dysfunction on exam (pain with palpation of superficial transverse perineii, bulbocavernosus insertion to perineal/central tendon and/or levator ani complex/iliococcygeus) * women with male sexual partners * history of undergoing pelvic floor physical therapy with internal manipulation including trigger point release as directed, with inability to meet goals of therapy despite appropriate pelvic floor physical therapy approach * able to read, write, and comprehend english sufficiently to offer informed consent exclusion criteria: * presence of intact hymen, preventing internal manipulation during pelvic floor physical therapy * pregnancy at the time of injection * breast feeding at the time of injection * history of myasthenia gravis, amyotrophic lateral sclerosis, lambert-eaton syndrome, allergy to botulinum toxin a, or other contraindication to botulinum toxin a injection * history of documented skin disorder of the vulva other than vaginal atrophy or lichen planus * prior pelvic radiation * stage ii-iv pelvic organ prolapse * has had a pelvic floor botulinum toxin a injection within the last 12 weeks * unable to provide informed consent

Keywords: pelvic pain dyspareunia pelvic floor dysfunction pelvic floor physical therapy chemodenervation botulinum toxin a vaginismus
establishing best treatment strategy for t4 esophageal cancer

Conditions: Esophageal Cancer TNM Staging Primary Tumor (T) T4

Summary: the goal of this clinical trial is to investigate the safety and efficacy of a new treatment approach for t4-stage esophageal cancer, which involves chemoradiotherapy after induction chemotherapy. the main questions it aims to answer are: * does the new induction chemotherapy followed by chemoradiation reduce esophageal perforation rate? * does the new induction chemotherapy followed by chemoradiation increase treatment response rate and patient survival? researchers will analyze the above data to see if the new treatment approach works to treat t4 esophageal cancer. participants will: * receive induction chemotherapy for 4 to 8 cycles, followed by chemoradiation therapy if downstage to t3 * visit the clinic once every week for checkups and tests * keep a diary of their symptoms

the treatment of t4-stage esophageal cancer is challenging because of a high esophageal perforation rate (19%) after concurrent chemoradiotherapy. this research aims to investigate whether a novel sequential chemoradiotherapy approach can improve the treatment response rate and reduce the incidence of esophageal perforation in participants with t4-stage esophageal cancer. the proposed novel treatment strategy involves induction chemotherapy for 4 to 8 cycles. it is followed by concurrent chemoradiotherapy if down-stage had been achieved by induction chemotherapy. the study will be conducted in two phases, starting with a phase i study to determine safety, followed by a phase ii study to evaluate overall efficacy. expected outcomes include improved treatment response rates and reduced esophageal perforation rates in t4-stage esophageal cancer, offering a better treatment option for these patients.

Eligibility criteria:
inclusion criteria: 1. histologically confirmed esophageal squamous cell carcinoma 2. tumor or lymph nodes invade adjacent organs (t4 stage) 3. aged between 18-70 years old 4. patient health status score eastern cooperative oncology group (ecog) performance status (ps) \<2 5. hemoglobin ≥ 10 g/l, absolute neutrophil count ≥ 2×10\^3/l, platelet count ≥ 100×10\^9/l, total bilirubin ≤ 1.5 mg/l, serum transaminases ≤ 105 u/l, creatinine clearance ≥ 40 ml/min. exclusion criteria: 1. previous chemotherapy history 2. myocardial infarction within the last three months 3. history of unstable angina, interstitial pneumonia, fibrotic lung disease, or severe emphysema 4. has other malignancies currently 5. uncontrolled infection 6. pregnancy or lactation 7. perforated esophagus at the time of diagnosis

Keywords: t4 esophageal cancer induction chemotherapy
the reproducibility of diffusion weighted magnetic resonance imaging for neuroendocrine tumor liver metastases

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor; Secondary Malignant Neoplasm of Liver

Summary: imaging with ct (computed tomography) or mri (magnetic resonance imaging) is normally used to see how tumors respond to treatment. if tumors shrink after therapy, doctors continue with the same treatment. on the other hand, growing tumors in a patient can bring about a change in therapy. unfortunately, it often takes three to six months, or even longer before the investigators see tumors shrink or grow on scans. doctors are looking for new imaging tools that can look at how tumors respond early on during treatment. this study will help us decide if such an mri technology called dwi (diffusion weighted imaging) can be used as a helpful imaging tool.


Eligibility criteria:
inclusion criteria: * histopathologic evidence of well differentiated neuroendocrine tumor of gastroenteropancreatic origin * evidence of metastatic disease of at least 2.0 cm in the liver by mri or ct imaging. * patient ≥18 years of age on the day of signing informed consent. exclusion criteria: * any contraindication to mri based on departmental mr questionnaire * inability to cooperate for an mr exam * patient has a history of a second active malignancy with evidence of metastases. patients with a history of resected prior malignancy or one that would not interfere with the mri results is allowed. * patient has known psychiatric or substance abuse disorders that would, in the opinion of the treating investigator, interfere with cooperation with the requirements of the trial.

Keywords: adrenal gland mri 11-122